Vor Biopharma (NASDAQ:VOR) Trading 9.3% Higher – Here’s What Happened

Vor Biopharma Inc. (NASDAQ:VOR)’s stock price traded up 9.3% on Thursday . The company traded as high as $14.73 and last traded at $14.6950. 260,078 shares were traded during mid-day trading, a decline of 73% from the average session volume of 965,606 shares. The stock had previously closed at $13.44.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $31.00 price target on shares of Vor Biopharma in a report on Monday, May 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Vor Biopharma in a report on Monday. Jefferies Financial Group upgraded shares of Vor Biopharma to a “strong-buy” rating in a report on Thursday, April 30th. Wedbush raised their price target on shares of Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a report on Thursday, May 14th. Finally, Wells Fargo & Company assumed coverage on shares of Vor Biopharma in a report on Thursday, March 19th. They issued an “overweight” rating and a $30.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $42.25.

Vor Biopharma Stock Performance

The firm’s 50 day simple moving average is $15.29 and its 200 day simple moving average is $13.71.

Vor Biopharma (NASDAQ:VOR) last announced its quarterly earnings data on Monday, March 30th. The company reported $307.61 EPS for the quarter. Equities research analysts predict that Vor Biopharma Inc. will post -2.51 earnings per share for the current year.

Insider Buying and Selling

In other Vor Biopharma news, Director Ra Capital Management, L.P. sold 165,150 shares of Vor Biopharma stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $15.77, for a total transaction of $2,604,415.50. Following the completion of the sale, the director directly owned 2,402,095 shares in the company, valued at approximately $37,881,038.15. The trade was a 6.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders have sold 3,002,903 shares of company stock worth $49,412,176. Insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On Vor Biopharma

Several institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. purchased a new position in shares of Vor Biopharma during the 4th quarter valued at approximately $36,000. Bank of America Corp DE increased its holdings in shares of Vor Biopharma by 679.3% during the 3rd quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock valued at $232,000 after purchasing an additional 4,144 shares in the last quarter. Squarepoint Ops LLC purchased a new position in shares of Vor Biopharma during the 3rd quarter valued at approximately $230,000. BNP Paribas Financial Markets increased its holdings in shares of Vor Biopharma by 497.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock valued at $296,000 after purchasing an additional 5,058 shares in the last quarter. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Vor Biopharma during the 3rd quarter valued at approximately $304,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).